Eisai Co. reported positive Phase 3 clinical trial results for its new Alzheimer's disease treatment, showing a 45% reduction in cognitive decline compared to placebo. The drug, developed in partnership with Biogen, is expected to file for regulatory approval in both Japan and the US later this year.